27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 2 | 2 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 1 | 0 |
| 2M Ago | 3 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $130.82, a high estimate of $171.00, and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 4.66% from the previous average price target of $125.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of BioNTech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $107.00 | - |
| Eliana Merle | UBS | Lowers | Neutral | $101.00 | $110.00 |
| Jessica Fye | JP Morgan | Lowers | Underweight | $90.00 | $99.00 |
| Etzer Darout | BMO Capital | Lowers | Outperform | $123.00 | $127.00 |
| Bill Maughan | Canaccord Genuity | Maintains | Buy | $171.00 | - |
| Chris Shibutani | Goldman Sachs | Lowers | Neutral | $100.00 | $113.00 |
| Bill Maughan | Canaccord Genuity | Maintains | Buy | $171.00 | - |
| Etzer Darout | BMO Capital | Announces | Outperform | $127.00 | - |
| Bill Maughan | Canaccord Genuity | Maintains | Buy | $171.00 | - |
| Bill Maughan | Canaccord Genuity | Raises | Buy | $171.00 | $168.00 |
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $107.00 | $133.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BioNTech. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of BioNTech's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on BioNTech analyst ratings.
All You Need to Know About BioNTech
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
BioNTech's Economic Impact: An Analysis
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: BioNTech's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -65.43%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: BioNTech's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 30.96%, the company may face hurdles in effective cost management.
Return on Equity (ROE): BioNTech's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.28%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): BioNTech's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: BioNTech's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!